Scheiman J M, Chey W D, Behler E M, Crause I, Elta G H
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109, USA.
J Clin Gastroenterol. 1996 Oct;23(3):170-3. doi: 10.1097/00004836-199610000-00002.
In clinical practice, eradication of Helicobacter pylori infection may be difficult due to medication side effects and the need for 2 weeks of therapy. Because therapies of shorter duration may improve patient compliance and reduce treatment side effects, we compared the efficacy and tolerability of two anti-H. pylori treatments of 1 week's duration. Patients with H. pylori infection were randomized to treatment with either (a) short-course triple therapy, composed-of bismuth subsalicylate (Pepto-Bismol, Procter & Gamble, Cincinnati, OH, U.S.A.) two tablets four times daily, amoxicillin 1 g (two 500-mg tablets) twice daily, and metronidazole 500 mg four times daily on days 5-7 or (b) omeprazole 40 mg twice a day with amoxicillin 1 g twice a day for 1 week. At least 4 weeks posttreatment, efficacy was evaluated with either histological evaluation of antral biopsies for H. pylori or 14C urea breath testing. Patients who failed initial therapy were allowed to cross over to the alternative treatment regimen after a minimum "wash-out" period of 5 weeks. Patients completed a diary during therapy to monitor both compliance and side effects. Thirty-four patients completed the study, 10 receiving both treatment regimens. Treatment with the shortcourse triple therapy eradicated H. pylori in 78.3% of treatments compared with 38% with the high-dose omeprazole/ amoxicillin combination (p < 0.05). Patients were highly compliant with both treatments, and mild side effects, such as transient loose stools or abdominal pain, were common in both groups. This is the first report from North America confirming the success of the short-course triple therapy for the eradication of H. pylori. The high-dose omeprazole/ amoxicillin regimen's eradication rate was markedly inferior to that achieved by the short-course triple therapy regimen and should not be used. Comparative studies of the short-course triple therapy regimen with other 7-day anti-H. pylori treatment regimen therapies are indicated.
在临床实践中,由于药物副作用以及需要进行为期2周的治疗,根除幽门螺杆菌感染可能会很困难。鉴于疗程较短的疗法可能会提高患者的依从性并减少治疗副作用,我们比较了两种为期1周的抗幽门螺杆菌治疗方案的疗效和耐受性。幽门螺杆菌感染患者被随机分配接受以下治疗之一:(a)短程三联疗法,即碱式水杨酸铋(必奇,宝洁公司,美国俄亥俄州辛辛那提)每日4次,每次2片,阿莫西林1克(两片500毫克片剂)每日2次,甲硝唑500毫克在第5至7天每日4次;或(b)奥美拉唑40毫克每日2次加阿莫西林1克每日2次,疗程1周。治疗后至少4周,通过对胃窦活检组织进行幽门螺杆菌组织学评估或14C尿素呼气试验来评估疗效。初始治疗失败的患者在至少5周的“洗脱”期后可改用替代治疗方案。患者在治疗期间填写日记以监测依从性和副作用。34名患者完成了研究,其中10名接受了两种治疗方案。短程三联疗法治疗幽门螺杆菌的根除率为78.3%,而高剂量奥美拉唑/阿莫西林联合治疗的根除率为38%(p<0.05)。患者对两种治疗的依从性都很高,两组中常见的轻微副作用如短暂性腹泻或腹痛。这是北美第一份证实短程三联疗法成功根除幽门螺杆菌的报告。高剂量奥美拉唑/阿莫西林方案的根除率明显低于短程三联疗法方案,不应使用。有必要对短程三联疗法方案与其他7天抗幽门螺杆菌治疗方案进行比较研究。